Cardiovascular events associated with different combined oral contraceptives. A review of current data

Drug Safety

Volumn 22, Issue 5, 2000, Pages 361-371

  Hannaford, Philip ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR; DESOGESTREL; ESTROGEN; GESTAGEN; GESTODENE; LEVONORGESTREL; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT;

BLOOD CLOTTING DISORDER; BLOOD PRESSURE; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FEMALE; HEART INFARCTION; HUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SMOKING; STROKE; VEIN THROMBOSIS;

EID: 0034101519     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200022050-00004     Document Type: Review

References (76)

1. 1. Jordan WM. Pulmonary embolism. Lancet 1961; II: 1146-7
2. 2. Hannaford PC, Owen-Smith V. Using epidemiological data to guide clinical practice: review of studies on cardiovascular disease and use of combined oral contraceptives. BMJ 1998; 316: 984-7
3. 3. World Health Organization Scientific Group on Cardiovascular Disease and Steroid Hormone Contraception. Cardiovascular disease and steroid hormone contraception: report of a World Health Organization scientific group. World Health Organization technical report series: 877. Geneva, Switzerland: World Health Organization, 1998
4. 4. Meirik O. Cardiovascular safety and combined oral contraceptives. Contraception 1998; 57: 135-6
5. 5. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. Lancet 1997; 349: 1202-9
6. 6. Lewis MA, Heinemann LAJ, Spitzer WO, et al. The use of oral contraceptives and the occurrence of acute myocardial infarction in young women: results for the transnational study on oral contraceptives and the health of young women. Contraception 1997; 56: 129-40
7. 7. Mant J, Painter R, Vessey M. Risk of myocardial infarction, angina and stroke in users of oral contraceptives: an updated analysis of a cohort study. Br J Obstet Gynaecol 1998; 105: 890-6
8. 8. Sidney S, Petitti DB, Queensberry Jr CP, et al. Myocardial infarction in users of low-dose oral contraceptives. Obstet Gynecol 1996; 88: 939-44
9. 9. Sidney S, Siscovick DS, Petitti DB, et al. Myocardial infarction and use of low-dose oral contraceptives: a pooled analysis of 2 US studies. Circulation 1998; 98: 1058-63
10. 10. Dunn N, Thorogood M, Faragher B, et al. Oral contraceptives and myocardial infarction: results of the MICA case-control study. BMJ 1999; 318: 1579-84
11. 11. Petitti DB, Sidney S, Queensberry CP. Oral contraceptive use and myocardial infarction. Contraception 1998; 57: 143-55
12. 12. Rosenberg L, Kaufman DW, Helmrich SP, et al. Myocardial infarction and cigarette smoking in women younger than 50 years of age. J Am Med Assoc 1985; 253: 2965-9
13. 13. Croft P, Hannaford PC. Risk factors for acute myocardial infarction in women: evidence from the Royal College of General Practitioners' oral contraception study. BMJ 1989; 298: 165-8
14. 14. Jick H, Jick S, Myers MW, et al. Risk of acute myocardial infarction and low-dose combined oral contraceptives. Lancet 1996; 347: 627-8
15. 15. Thorogood M. Stroke and steroid hormonal contraception. Contraception 1998; 57: 157-67
16. 16. Lidegaard Ø. Oral contraception and risk of cerebral thromboembolic attack: results of a case-control study. BMJ 1993; 306: 956-63
17. 17. Schwartz SM, Petitti DB, Siscovick DS, et al. Stroke and use of low-dose oral contraceptives in young women: a pooled analysis of two US studies. Stroke 1998; 29: 2277-84
18. 18. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study. Lancet 1996; 348: 498-505
19. 19. Carolei A, Marini C, De Matteis G. History of migraine and risk of cerebral ischaemia in young adults. Lancet 1996; 347: 1503-6
20. 20. Oleckno WA. The risk of stroke in young adults: an analysis of the contribution of cigarette smoking and alcohol consumption. Public Health 1988; 102: 45-55
21. 21. Heinemann LA, Lewis MA, Spitzer WO, et al. Thromboembolic stroke in young women. A European case-control study on oral contraceptives. Contraception 1998; 57: 29-37
22. 22. Heinemann LAJ, Lewis MA, Thorogood M, et al. Oral contraceptives and risk of thromboembolic stroke. BMJ 1997; 315: 1502-4
23. 23. Tzourio C, Tchindrazanarivelo A, Iglesias S, et al. Case-control study of migraine and risk of ischaemic stroke in young women. BMJ 1995; 310: 830-3
24. 24. Chang CL, Douglas M, Poulter N, et al. Migraine and stroke in young women: case-control study. BMJ 1999; 318: 13-8
25. 25. Lidegaard Ø, Kreiner S. Cerebral thrombosis and oral contraceptives. Contraception 1998; 57: 303-14
26. 26. Poulter NR, Chang CL, Farley TMM, et al. Effect on stroke of different progestogens in low estrogen dose oral contraceptives. Lancet 1999; 354: 301-2
27. 27. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: results from an international, multicentre, case-control study. Lancet 1996; 348: 505-10
28. 28. Jick SS, Myers MW, Jick H. Risk of idiopathic cerebral haemorrhage in women on oral contraceptives with differing progestogen components. Lancet 1999; 354: 302-3
29. 29. Realini JP, Encarnacion CE, Chintapalli KN, et al. Oral contraceptives and venous thromboembolism: a case-control study designed to minimize detection bias. J Am Family Pract 1997; 10: 315-21
30. 30. Bloemenkamp KWM, Rosendaal FR, Büller HR, et al. Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. Arch Intern Med 1999; 159; 65-70
31. 31. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995; 346: 1575-82
32. 32. Jick H, Jick SS, Gurewich V, et al. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589-93
33. 33. Suissa S, Blais L, Spitzer WO, et al. First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception 1997; 56: 141-6
34. 34. Lidegaard Ø, Edstrøm B, Kreiner S. Oral contraceptives and venous thromboembolism. Contraception 1998; 57: 291-301
35. 35. Herings RMC, Urquhart J, Leufkens HGM. Venous thromboembolism among new users of different oral contraceptives. Lancet 1999; 354: 127-8 [Published erratum apprears in Lancet 1999; 354: 1478]
36. 36. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, et al. Venous thromboembolism and oral contraceptives [letter]. Lancet 1999; 354: 1469
37. 37. Pabinger I, Kyrle PA, Heistinger M, et al. Thrombosis risk of women with hereditary antithrombin III, protein C- and protein S- deficiency taking oral contraception medication. Thromb Haemost 1994; 71; 458-552
38. 38. Vandenbroucke JP, Koster T, Briët E, et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-7
39. 39. Andersen BS, Olsen J, Neilsen GL, et al. Third generation oral contraceptives and heritable thrombophilia as risk factors of non-fatal venous thrombolism. Thromb Haemost 1998; 79: 28-31
40. 40. Martinelli I, Taioli E, Bucciarelli P, et al. Interaction between G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. Arterioscler Thromb Vasc Biol 1999; 19: 700-3
41. 41. Martinelli I, Sacchi E, Landi G, et al. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med 1998; 338: 1793-7
42. 42. De Bruijn SFTM, Stam J, Koopman MMW, et al. Case-control study of cerebral sinus thrombosis in oral contraceptive users who are carriers of hereditary prothrombotic conditions. BMJ 1998; 316: 589-92
43. 43. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low estrogen oral contraceptives on venous thromboembolic disease. Lancet 1995; 346: 1582-8
44. 44. Spitzer WO, Lewis MA, Heinemann LAJ, et al. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. BMJ 1996; 312: 83-8
45. 45. Lewis MA, Heinemann LAJ, MacRae KD, et al. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. Contraception 1996; 54: 5-13
46. 46. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM. et al. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995; 346: 1593-6
47. 47. Farmer RDT, Lawrenson RA, Thompson CR, et al. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 1997; 349: 83-8
48. 48. Bennet L, Odeberg H. Resistance to activated protein C, highly prevalent amongst users of oral contraceptives with venous thromboembolism. J Intern Med 1998; 244: 27-32
49. 49. Vasilakis C, Jick SS, Jick H. The risk of venous thromboembolism in users of postcoital contraceptive pills. Contraception 1999; 59: 79-83
50. 50. Farmer RDT, Todd JC, Lewis MA, et al. The risks of venous thromboembolic disease among German women using oral contraceptives: a database study. Contraception 1998; 57: 67-70
51. 51. Todd JC, Lawrenson R, Farmer RDT, et al. Venous thromboemholic disease and combined oral contraceptives: a re-analysis of the MediPlus database. Hum Reprod 1999; 14: 1500-5
52. 52. De Bruijn SFTM, Stam J, Vandenbroucke JP, et al. Increased risk of cerebral venous thrombosis with third-generation oral contraceptives [letter]. Lancet 1998; 351: 1404
53. 53. Martinelli I, Taioli E, Palli D, et al. Risk of cerebral vein thrombosis and oral contraceptives [letter]. Lancet 1998; 352: 326
54. 54. Weiss NS. Bias in studies of venous thromboembolism in relation to the use of new formulations of oral contraceptives. Contraception 1997; 55: 189-90
55. 55. Vandenbroucke JP, Bloemenkamp KWM, Heimerhorst FM, et al. Risk of oral contraceptives and recency of market introduction. Contraception 1997; 55: 191-2
56. 56. Inman WHW, Vessey MP, Westerholm B, et al. Thromboembolic disease and the steroidal content of oral contraceptives. A report to the Committee on Safety of Drugs. BMJ 1970; 2: 203-9
57. 57. Böttiger LE, Boman G, Eklund G, et al. Oral contraceptives and thromboembolic disease: effects of lowering estrogen content. Lancet 1980; 1: 1097-101
58. 58. Meade TW, Greenberg G, Thompson SG. Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50- and 30-μg estrogen preparations. BMJ 1980; 2: 1157-61
59. 59. Poulter NR, Chang CL, Marmot M, et al. Third-generation oral contraceptives and venous thrombosis [letter]. Lancet 1997; 349: 732
60. 60. Lewis MA, MacRae KD, Kühl-Habich D, et al. The differential risk of oral contraceptives: the impact of full exposure history. Hum Reprod 1999; 14: 1493-9
61. 61. Jick H, Jick S. Third-generation oral contraceptives and venous thrombosis. Lancet 1997; 349: 731-2
62. 62. Farley TMM, Meirik O, Marmot MG, et al. Oral contraceptives and risk of venous thrombolism: impact of duration of use. Contraception 1998; 57: 61-4
63. 63. Walker AM. Newer oral contraceptives and the risk of venous thromboembolism. Contraception 1998; 57: 169-81
64. 64. Crook D, Godsland I. Safely evaluation of modern oral contraceptives. Contraception 1998; 57: 189-201
65. 65. Winkler UH. Blood coagulation and oral contraceptives. Contraception 1998; 57: 203-9
66. 66. Nichols M, Robinson G, Bounds W, et al. Effect of four combined oral contraceptives on blood pressure in the pill-free interval. Contraception 1993; 47: 367-76
67. 67. Narkiewicz K, Graniero GR, D'Este D, et al. Ambulatory blood pressure in mild hypertensive women taking oral contraceptives. Am J Hypertens 1995; 8: 249-53
68. 68. Chasan-Taber L, Willet WC, Manson JE, et al. Prospective study of oral contraceptives and hypertension among women in the United States. Circulation 1996; 94: 483-9
69. 69. Cardoso F, Polónia J, Santos A, et al. Low-dose oral contraceptives and 24-hour ambulatory blood pressure. Int J Gyn Obstet 1997; 59: 237-43
70. 70. Rosing J, Tans G, Nicolaes GAF, et al. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol 1997; 97: 233-8
71. 71. Kluft C, de Maat MPM, Heinemann LAJ, et al. Importance of levonorgestrel dose in oral contraceptives for effects on coagulation. Lancet 1999; 354: 832-3
72. 72. Rosing J, Middledorp S, Curvers J, et al. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet 1999; 354: 2036-40
73. 73. Vandenbroucke JP, Rosendaal FR. End of the line for 'third-generation-pill' controversy? Lancet 1997; 349: 1113-4
74. 74. Hannaford PC, Webb AMC on behalf of participants at an International Workshop. Evidence-Guided Prescribing of Combined Oral Contraceptives. Consensus Statement. Contraception 1996; 54: 125-9
75. 75. Winkler UH. Role of screening for vascular disease in pill users: the homeostatic system. In: Hannaford PC, Webb AMC, editors. Evidence-guided prescribing of the pill. Carnforth, UK: Parthenon Publishing, 1996: 109-20
76. 76. Vandenbroucke JP, van der Meer FJM, Helmerhorst FM, et al. Factor V Leiden: should we screen oral contraceptive users and pregnant women? BMJ 1996, 313; 1127-30